Device company Nemera and UK-based pharma company Therakind have announced a deal that will allow Nemera to add Therakind’s DriDose intranasal dry powder delivery technology to its portfolio. Therakind, which is developing several nasal DPI products itself, has 2 multi-dose versions of the device and a unit-dose version.
Nemera’s current products for nasal delivery of aqueous formulations include the SP270+ and SP370+ multi-dose nasal pumps and the UniSpray single metered dose nasal pump. Through the new partnership with Therakind, the announcement says, Nemera “broadens its innovative nasal portfolio to include a complete dry powder delivery platform, further enhancing its end-to-end offering for pharmaceutical and biotechnology partners.”
Therakind CEO Susan Conroy commented, “We are delighted to partner with Nemera, known for its expertise in drug delivery solutions and novel device industrialization. As a market leader in devices with a global presence, Nemera is an ideal partner for the DriDose portfolio industrialization and expansion.”
Nemera VP of the Ear, Nose and Throat Business Dimitri Grasswill said, “We are thrilled to partner with Therakind and benefit from their strong track record in pharmaceutical development and regulatory approvals. The innovative DriDose technology will open Nemera to new therapeutic areas in nasal drug delivery and will significantly improve patients’ lives. It perfectly complements our product portfolio especially by targeting unmet needs in systemic and non-systemic treatments.”
Read the Nemera and Therakind press release
